Literature DB >> 24874283

Use of antacids, alginates and proton pump inhibitors: a survey of the general Danish population using an internet panel.

Anders Lødrup1, Christina Reimer, Peter Bytzer.   

Abstract

OBJECTIVE: Both over-the-counter medicine, such as antacids or alginates, and proton pump inhibitors (PPI) are used for treating acid-related disorders. We sought to describe what characterizes users of these different medicines, including long-term PPI users within the general population.
METHOD: A cross-sectional survey was conducted in an internet panel representative of the Danish adult population in 2012. Data queried included antacid/alginate and PPI use, reason for therapy, co-medication, and presence of upper gastrointestinal symptoms. Long-term PPI use was defined as using PPI ≥1/3 of the last year (∼120 days). Risk of long-term PPI use was estimated by logistic regression.
RESULTS: A total of 18,223 people received the questionnaire, of which 52% (9390) responded. Antacid/alginate use was reported by 23%; 16% reported use of only antacid/alginate. PPI use was reported by 13.6%; 6.2% were defined as long-term PPI users. Antacid/alginate users were younger, used less co-medication, had most often started on therapy because of reflux symptoms, and had less often ongoing symptoms. Risk of long-term PPI use appeared to be increased in male gender, by renewing PPI prescription by phone/e-mail, using co-medication, and having started on PPI for several reasons. Combination of antacid/alginate and PPI was reported by approximately 50% of those on therapy with weekly or daily symptoms.
CONCLUSION: 23% of Danish adults were using antacids or alginates and 14% were using PPI, of which one-half were on long-term therapy. Prescription renewal by phone or e-mail and use of other prescription medication were associated with long-term PPI use, indicating a behavioral pattern, in which unnecessary PPI therapy may be maintained.

Entities:  

Keywords:  alginate; antacid; dyspepsia; general population; internet panel; over-the-counter medicine; proton pump inhibitor; reflux

Mesh:

Substances:

Year:  2014        PMID: 24874283     DOI: 10.3109/00365521.2014.923504

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study.

Authors:  Anton Pottegård; Anne Broe; Jesper Hallas; Ove B Schaffalitzky de Muckadell; Annmarie T Lassen; Anders B Lødrup
Journal:  Therap Adv Gastroenterol       Date:  2016-05-26       Impact factor: 4.409

2.  General practice variation when initiating long-term prescribing of proton pump inhibitors: a nationwide cohort study.

Authors:  P F Haastrup; S Rasmussen; J M Hansen; R D Christensen; J Søndergaard; D E Jarbøl
Journal:  BMC Fam Pract       Date:  2016-05-28       Impact factor: 2.497

3.  Burden of drug use for gastrointestinal symptoms and functional gastrointestinal disorders in France: a national study using reimbursement data for 57 million inhabitants.

Authors:  Philippe Tuppin; Sébastien Rivière; David Deutsch; Christelle Gastaldi-Menager; Jean-Marc Sabaté
Journal:  Therap Adv Gastroenterol       Date:  2019-07-12       Impact factor: 4.409

Review 4.  When does proton pump inhibitor treatment become long term? A scoping review.

Authors:  Peter Fentz Haastrup; Dorte Ejg Jarbøl; Wade Thompson; Jane Møller Hansen; Jens Søndergaard; Sanne Rasmussen
Journal:  BMJ Open Gastroenterol       Date:  2021-02

5.  Placebo-Controlled Discontinuation of Long-Term Acid-Suppressant Therapy: A Randomised Trial in General Practice.

Authors:  Jon Eik Zwisler; Dorte Ejg Jarbøl; Annmarie Touborg Lassen; Jakob Kragstrup; Niels Thorsgaard; Ove B Schaffalitzky de Muckadell
Journal:  Int J Family Med       Date:  2015-07-12

6.  Heartburn-Related Internet Searches and Trends of Interest across Six Western Countries: A Four-Year Retrospective Analysis Using Google Ads Keyword Planner.

Authors:  Mikołaj Kamiński; Igor Łoniewski; Agata Misera; Wojciech Marlicz
Journal:  Int J Environ Res Public Health       Date:  2019-11-20       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.